Wedoany.com Report on Feb 5th, The French National Agency for the Safety of Medicines and Health Products (ANSM) announced that the 100 mg tablet of the antipsychotic drug Largactil has been back in supply since January 22, 2026. The agency stated in its announcement: "Due to delivery delays in the distribution chain, the medication will be gradually made available to patients." This means the temporary restrictions implemented since late last October have now been lifted.

Largactil (generic name chlorpromazine) is a first-generation antipsychotic, primarily used to treat acute and chronic psychotic symptoms in adults and certain severe behavioral disorders in children over the age of 6. The supply shortage that emerged last autumn mainly affected the 100 mg strength, caused by production delays stemming from quality concerns regarding an excipient.

With the chlorpromazine supply returning to normal, doctors can now prescribe the 100 mg dosage again, no longer being limited to the 25 mg tablets. Pharmacists are also not allowed to dispense 25 mg tablets in place of 100 mg tablets without the patient presenting a new prescription. ANSM specifically reminds that any dosage changes must be clearly explained to patients to ensure they understand the new treatment regimen. The announcement noted: "This particularly concerns patients who were taking multiple Largactil 25 mg tablets per dose during the period of tight supply."

Following the severe shortage in 2025, ANSM indicated on January 8th that the situation was "gradually improving," but still noted that supply remained "fragile and highly dependent on the regularity of laboratory supplies." The restoration of chlorpromazine supply marks an alleviation of the shortage issue for this critical psychiatric medication.